ArticleBMC cardiovascular disorders2019
In-hospital and post-discharge outcomes of pediatric acute myocarditis underwent after high-dose steroid or intravenous immunoglobulin therapy.
Article in BMC cardiovascular disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Effect of intravenous immunoglobulin and steroids in acute myocarditis in children: a systematic review and network meta-analysis.Pediatric research · 2026Pooled it
- Corticosteroid in anti-inflammatory treatment of pediatric acute myocarditis: a systematic review and meta-analysis.Italian journal of pediatrics · 2023Pooled it
- Clinical and virological impacts of human parvovirus B19 epidemics on fulminant myocarditis in childhood.BMC pediatrics · 2026Article
- Intravenous Immunoglobulin Efficacy and Safety in Paediatric Patients Diagnosed with Acute Myocarditis.Journal of clinical medicine · 2025Article
- A comparative review of myocarditis in pediatrics versus adults: pathogenesis, diagnosis, and management.Frontiers in immunology · 2025Review
- Outbreak of paediatric myocarditis associated with parvovirus B19 infection in Italy, January to October 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Clinical Application of Extracorporeal Membrane Oxygenation in the Treatment of Fulminant Myocarditis.Reviews in cardiovascular medicine · 2024Review
- Article
- Fulminant myocarditis associated with human rhinovirus A66 infection: a case report.Frontiers in pediatrics · 2024Article
- Pediatric Myocarditis.Cardiology and therapy · 2023Review
- Pediatric Myocarditis: What Have We Learnt So Far?Journal of cardiovascular development and disease · 2022Review
- Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.The New England journal of medicine · 2021Article
- Challenges of Diagnosing Viral Myocarditis in Adolescents in the Era of COVID-19 and MIS-C.Case reports in pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-dose steroids and intravenous immunoglobulin (IVIG) are controversial treatments for pediatric patients with acute myocarditis. This study aimed to investigate their efficacies in the Taiwanese pediatric population.
methodsThis study evaluated 5563 acute myocarditis patients from the Taiwan's National Health Insurance Research Database and identified 1542 pediatric patients hospitalized for acute myocarditis between January 1, 2001 and December 31, 2011. The exclusion criteria were age of > 11 years, associated cardiovascular comorbidities, autoimmune disease, malignancy before the index hospitalization, extracorporeal membrane oxygenation, intra-aortic balloon pumping, and dual therapy using IVIG and high-dose steroids.
resultsAfter 2:1 propensity score matching, we identified 208 subjects without steroid therapy and 104 subjects who received high-dose steroids. The mean age in that cohort was 2.6 ± 2.9 years, and high-dose steroid therapy had no significant effects on major in-hospital complications and post-discharge outcomes. After 2:1 propensity score matching, we identified 178 subjects without IVIG therapy and 89 subjects who received IVIG. The mean age in that cohort was 2.0 ± 2.1 years, and IVIG had no significant effects on the major outcomes.
conclusionsThe present study revealed that high-dose steroid or IVIG therapy had no significant effects on major in-hospital complications, late heart failure hospitalization, and long-term mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.